Study (author/year) | Country | Primary disease | Type of THA | Type of BPs | Control group | Men | Women | Treatment duration | Time of following | Loss to follow-up | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BPs | control | BPs | control | BPs | control | BPs | control | BPs | control | ||||||
Tapaninen TS/2010 [18] | Finland | Primary hip osteoarthritis | Uncemented | Alendronate (G3) | Calcium | 2 | 5 | 5 | 4 | 0.5Â year | 0.5Â year | 5Â years | 5Â years | 0 | 0 |
Trevisan C/2010 [19] | Italy | NA | Uncemented | Clodronate (G2) | No medication | 26 | 27 | 16 | 22 | 1Â year | No medication | 1Â year | 1Â year | 4 | 8 |
Arabmotlagh M/2009 [20] | Germany | Degenerative osteoarthritis | Uncemented | Alendronate (G3) | No medication | 16 | 9 | 13 | 11 | 5/10Â weeks | No medication | 6Â years | 6Â years | 2 | 1 |
Yamasaki S/2007 [21] | Japan | Osteoarthritis secondary to acetabular dysplasia | Uncemented | Risedronate (G3) | Placebo | 2 | 2 | 17 | 19 | 0.5Â year | 0.5Â year | 0.5Â year | 0.5Â year | 3 | 0 |
Fokter SK/2006 [22] | Slovenia | Primary or secondary osteoarthritis | Cemented | Etidronate (G1) | Placebo | 6 | 3 | 12 | 10 | 1Â year | 1Â year | 1Â year | 1Â year | 2 | 1 |
Arabmotlagh M/2006 [23] | Germany | Degenerative primary osteoarthritis | Uncemented | Alendronate (G3) | Placebo | 14 | 12 | 13 | 12 | 0.5Â year | 0.5Â year | 52Â weeks | 52Â weeks | 0 | 0 |
Yamaguchi K/2004 [24] | Japan | Osteoarthritis secondary to hip dysplasia | Uncemented | Etidronate (G1) | No medication | 5 | 2 | 26 | 22 | 1Â year | No medication | 30Â months | 30Â months | 2 | 0 |
Iwamoto N/2011 [25] | Japan | Osteoarthritis | Uncemented | Alendronate (G3) | No medication | 4 | 5 | 16 | 17 | 48Â weeks | no medication | 48Â weeks | 48Â weeks | 2 | 0 |
Kinov P/2006 [26] | Bulgaria | Osteoarthritis, osteonecrosis, or hip fracture | Cemented or hybrid | Risedronate (G3) | Placebo | 4 | 5 | 8 | 7 | 0.5Â year | 0.5Â year | 0.5Â year | 0.5Â year | 0 | 0 |
Shetty N/2006 [27] | England | Primary or secondary osteoarthritis | Hybrid | Pamidronate (G2) | Placebo | 12 | 10 | 6 | 9 | 50Â days | 50Â days | 5Â years | 5Â years | 1 | 1 |
Scott DF/2013 [28] | America | NA | Uncemented | Zoledronate (G3) | Placebo + calcium | 12 | 11 | 15 | 13 | Twice administration | Twice administration | 2Â years | 2Â years | 0 | 0 |
Yukizawa Y/2017 [29] | Japan | Osteoarthritis | Uncemented | Alendronate (G3) | No medication | 4 | 7 | 14 | 9 | ≥ 2 years | no medication | ≥ 9 years | ≥ 9 years | 0 | 0 |
Muren O/2015 [30] | Sweden | Osteoarthritis | Uncemented | Risedronate (G3) | Placebo + calcium | 20 | 18 | 10 | 13 | 0.5Â year | 0.5Â year | 4Â years | 4Â years | 0 | 0 |
Nehme A/2003 [31] | Lebanon | Degenerative hip disease | Cemented | Alendronate (G3) | Placebo + calcium | NA | NA | NA | NA | 2Â years | 2Â years | 2Â years | 2Â years | 0 | 0 |